Note: The Allos logo and FOLOTYN name are registered trademarks of Allos Therapeutics, Inc.

Editor’s Note: This press release is also available under the Media section of Allos Therapeutics’ website at www.allos.com

References:

1. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood. 1997;89(11):3909-3908.

2. Hennessy BT, Hanrahan EO, Daly PA. Non-Hodgkin lymphoma: an update [review]. Lancet Oncol. 2004;5(6):341-353.

3. O'Leary HM, Savage KJ. Novel therapies in peripheral T-cell lymphomas [review]. Curr Oncol Rep. 2008;134(5):202-207.

4. Savage KJ, Chhanabhai M, Gascoyne RD, et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004;15(10):1467-75.

5. Savage KJ. Peripheral T-cell Lymphomas. Blood Rev. 2007; 21:201-216.

Copyright Business Wire 2010

If you liked this article you might like

Monday's Top 10 Articles, Videos on TheStreet

Spectrum Pharma: The Growth Party is Over

Allos Stock Gaps Down On Today's Open (ALTH)

Biotech Stock Mailbag: Amarin, Spectrum, Arena

Next Step for Amag's Board: Fire CEO, Sell the Company.

Next Step for Amag's Board: Fire CEO, Sell the Company.